Macrogenics Inc (NASDAQ:MGNX) price on Friday, July 25, fall -3.93% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $1.71.
A look at the stock’s price movement, the close in the last trading session was $1.78, moving within a range at $1.67 and $1.78. The beta value (5-Year monthly) was 1.589. Turning to its 52-week performance, $5.77 and $0.99 were the 52-week high and 52-week low respectively. Overall, MGNX moved 30.53% over the past month.
Macrogenics Inc’s market cap currently stands at around $107.88 million, with investors looking forward to this quarter’s earnings report slated for on 2025-May-13.
Analysts have a consensus estimate of 28.06M for the company’s revenue for the quarter, with a low and high estimate of 7.5M and 75.9M respectively. The average forecast suggests up to a 159.87% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 91.68M, representing a -38.86% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that MGNX is a Hold. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
8 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 2 analyst(s) rate the stock as a Hold, 6 recommend MGNX as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
MGNX’s current price about 13.89% and 14.47% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 59.62, while 7-day volatility ratio is 9.14% and 8.30% in the 30-day chart. Further, Macrogenics Inc (MGNX) has a beta value of 1.68. Analysts have given the company’s stock an average 52-week price target of $2.5, forecast between a low of $2 and high of $3. Looking at the price targets, the low is -16.96% off current price level while to achieve the yearly target high, price needs to move -75.44%. Nonetheless, investors will most likely welcome a -46.2% jump to $2.5 which is the analysts’ median price.
If we refocus on Macrogenics Inc (NASDAQ:MGNX), historical trading data shows that trading volumes averaged 0.69 over the past 10 days and 1.23 million over the past 3 months. The company’s latest data on shares outstanding shows there are 63.09 million shares.
The 8.16% of Macrogenics Inc’s shares are in the hands of company insiders while institutional holders own 79.47% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 4.08 million on 2025-07-15, giving us a short ratio of 3.33. The data shows that as of 2025-07-15 short interest in Macrogenics Inc (MGNX) stood at 795.0 of shares outstanding, with shares short falling to 5.53 million registered in 2025-06-13. Current price change has pushed the stock -67.92% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the MGNX stock continues to rise going into the next quarter.
